K
74.34
-3.86 (-4.94%)
| Penutupan Terdahulu | 78.20 |
| Buka | 77.66 |
| Jumlah Dagangan | 1,034,399 |
| Purata Dagangan (3B) | 771,822 |
| Modal Pasaran | 5,800,305,152 |
| Harga / Pendapatan (P/E TTM) | 75.09 |
| Harga / Pendapatan (P/E Ke hadapan) | 70.92 |
| Harga / Jualan (P/S) | 7.41 |
| Harga / Buku (P/B) | 9.06 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 27 Oct 2026 |
| Margin Keuntungan | -3.52% |
| Margin Operasi (TTM) | 9.63% |
| EPS Cair (TTM) | -0.240 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 72.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.17% |
| Nisbah Semasa (MRQ) | 3.66 |
| Aliran Tunai Operasi (OCF TTM) | 44.03 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 25.15 M |
| Pulangan Atas Aset (ROA TTM) | -1.77% |
| Pulangan Atas Ekuiti (ROE TTM) | -3.81% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Menaik |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Kiniksa Pharmaceuticals Interna | Bercampur | Menaik |
AISkor Stockmoo
0.1
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.13 |
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.80% |
| % Dimiliki oleh Institusi | 97.31% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| COLE G BRADLEY | - | 80.92 | -8,173 | -661,359 |
| LEVY RICHARD S | - | - | 0 | 0 |
| Jumlah Keseluruhan Kuantiti Bersih | -8,173 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -661,359 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 80.92 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| LEVY RICHARD S | Pengarah | 01 Aug 2026 | Pelaksanaan pilihan | 403 | - | - |
| COLE G BRADLEY | Pengarah | 29 Jul 2026 | Jual (-) | 3,673 | 80.92 | 297,219 |
| COLE G BRADLEY | Pengarah | 29 Jul 2026 | Dibuang (-) | 4,500 | 80.92 | 364,140 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |